Observe Medical ASA (OBSRV) Earnings Call Transcript & Summary

August 26, 2024

Oslo Bors NO Health Care Health Care Equipment and Supplies earnings 35 min

Earnings Call Speaker Segments

Jorgen Mann

executive
#1

Good morning, and welcome to the half year report from Observe Medical. I hope everyone has joined us by now and that you can hear us. I'll present in English, despite being Danish, because I believe that will give the greatest transparency regarding what gets said. Kindly take note of the company rights and disclaimer notice. All of these materials have been uploaded to our home page. So you can pick up these documents afterwards, should you need further details. Today's presenters are myself. My name is Jørgen Mann, I'm Danish. I recently took on the CEO position at Observe Medical since April as an interim, but also now as a permanent CEO since quite recently. Our second speaker will be our CFO, Johan Fagerli, who will give you some numbers on the first half year of 2024. The agenda for today covers some of the highlights that we have seen during the first half year, and also the progress. So you can see how we are progressing compared to what has been communicated on earlier occasions. We will also give you some key financials and also the outlook for the rest of the year and also something into the following years in terms of financial overall numbers.

Jorgen Mann

executive
#2

So the way we’d frame the whole thing — what we are and what we’re trying to achieve — is that we’re a medtech platform. That’s our own view of ourselves. We’re heavily involved in two particular segments. One is the urine measurement space, and that’s where our main focus sits right now when it comes to commercializing the opportunities inside the portfolio we control, which we took over from the Convatec portfolio, and also when it comes to launching products of our own within that platform. The ultrasound segment is likewise part of where we’re heading strategically. It’s a bit different, as we communicated after the rights issue late last year. We’re now looking in a direction where we’re pursuing partnerships in the Ultrasound segment so that journey can continue in the best possible and most profitable way for — also for Observe Medical. In the full year report earlier this year, we also brought in a new segment that we call distribution opportunities. With the latest changes, we’re now present with 24 distributors across Europe, Middle East, Asia and also now South America. So this platform is something we intend to use to launch products as well — third-party products from other companies, innovative companies that can benefit from this commercial platform going forward.

Jorgen Mann

executive
#3

When we look at 2024 and the H1 highlights, our main target is what we're focused on. Continuing the rollout of the UnoMeter 500 and the UnoMeter Abdo-Pressure through that distribution network I mentioned earlier has been the central focus. And we're also continuously working to expand our geographical footprint, and we're succeeding in that expansion as well. So that one is on plan, and it's also a crucial platform for the future launches I'll tell you about in a minute. We're also experiencing — it's now roughly 2 years ago that Convatec exited the market quite abruptly. As expected, we're now also seeing an increasingly competitive situation in the market. And in that context, of course, the UnoMeter 500 is under some pressure as well. And beneath that headline, we're also very happy to be able to say that the launch of the UnoMeter Safeti, the differentiated unique product, is basically now being launched as we speak, so that is our answer to this. But of course, we're fighting again now to keep growing within our market share. As I also hinted at at the start of this presentation, we've changed the management within the company, with Johan joining as CFO in the early spring.

Jorgen Mann

executive
#4

And at this point I’m also there in the CEO role. Right now we’re intensely focused on the commercial path we’re on. We’re equally focused on getting the pipeline of new products into the market—those are the ones that will take us from where we stand today to a very different financial position, a very different market-share position, and so on. You’ll see some of that reflected in certain numbers later. We also want a tighter approach to our costs and our spending. We clearly want to reach a point where the company can generate its own cash—positive cash flow. Within that framework, there are three main priorities: launching the new products, growing the top line, and also keeping full control of our costs from that standpoint. As I said earlier, and as noted in the full-year report as well, the commercial launch of the UnoMeter Safeti Plus is underway now. It began in June with outreach to all of our distributors. The feedback has been very positive, as we expected, because every one of them had been waiting for us to bring the Safeti Plus to launch.

Jorgen Mann

executive
#5

And at this point we expect the complete launch as well, with full capacity, and deliveries beginning either very late September — sorry — or early October. So the Safeti Plus launch is going according to plan. For context, Safeti Plus is a product that was also included in the Convatec portfolio. It was the portion of the Convatec portfolio accounting for roughly 70%, 75% of the entire revenue Convatec was generating, which came to about NOK 200 million in total. So launching this product matters enormously to us. Our distributors will also receive what you could call an upgraded tool relative to the UnoMeter 500. And from a profitability standpoint for our company, this product will likewise, in terms of both revenue and profitability, represent an extremely important step for us. As you probably know, we launched UnoMeter 500 late last year. And over the spring, we received the first feedback from the market, which has been positive and has also pointed to areas where the product needed improvement. Not regarding the core functionality of the product, but even so, certain areas that required improvement.

Jorgen Mann

executive
#6

That's why we've now introduced Edition 2 of the UnoMeter 500. The launch has happened. Units are going out right now. We're also really proud that, in what you could call a ramp-up or scale-up phase, we can handle both the planning side of the launch and our portfolio — it's a big step for us that we can meet demand for the UnoMeter 500 and at the same time guarantee that product's quality is second to none. We also wrapped up a private placement in June that brought in NOK 22 million gross. And we're carrying on down that road, with the next move being a repair mission coming up shortly in late September. On top of that, we're progressing — as announced before — on an undertaking with the strategic manufacturer we currently work with in China. Biim, the strategic journey we set out earlier in the year: we've made meaningful progress there and have now signed an LOI with a well-known American company in the imaging space. Together with them, we're now looking into what the best possible form of cooperation would be going forward.

Jorgen Mann

executive
#7

We anticipate wrapping up that process during Q4 2024. Those are the main points from the past 6 months. The largest of them is undoubtedly the Safeti Plus launch. As I trust you gathered from what I said earlier, this product was the heart of the Convatec portfolio. Going forward, it will sit at the heart of what we offer — our product portfolio. This slide was also shown earlier this year at the full year presentation. And it lays out our plans when it comes to launching products. This is the pipeline before us. So what it shows is that the first three products in the UnoMeter portfolio for urine measurement have all now been launched. And as I said, the Safeti Plus marks a very important step. With it, we are reaching a position where we hold the same strength Convatec had at the time we struck the deal with them. So we have now rebuilt Convatec's strength with the portfolio as it stands. As you will also see looking at the 2025 perspective, we have specific projects that will carry us further. We will differentiate even the manual UnoMeter segment with the UnoMeter Max.

Jorgen Mann

executive
#8

We're also planning to launch the UnoMeter Sippi in the second half of 2025. That's a very important step for us, since it will push us even further into a market-leading position — which is definitely what we're aiming for — and it will also give us access to increased revenue and definitely higher profits as well, supporting our journey toward a strong financial organization. As I already mentioned, the Biim strategic journey — after the rights issue in December, a new direction was set out for that part of our company, saying we wanted to find a strategic partner to grow this segment. Over the last 4 months we've spent time evaluating different opportunities, different partnerships that we could enter into. And now we've made a decision on who could be the best potential partner going forward. As I mentioned, a U.S. industrial player within the imaging field. And we're confident that this is going to be a very interesting journey over the next 3 or 4 months. The due diligence process has now commenced. We're keeping an open mind in terms of how the partnership will finally look, but they offer a certain market potential on their own. And together with us, we do set out a very strong portfolio and a strong market presence that we expect to be able to exploit going forward.

Jorgen Mann

executive
#9

All right, please proceed. The floor is yours.

Johan Fagerli

executive
#10

<<foreign_lang>>

Jorgen Mann

executive
#11

Thanks for that, Johan. So, as a general remark on the figures, we're at a point now where we believe we've made up in full for the adverse impact from shutting down the Nordic business, and that was the sole revenue-producing operation we had through last year. What we're doing now is substituting it with what we regard as our strategic priority, which means the urine measurement portfolio sold under the UnoMeter brand. We're pretty pleased with how that's going. That said, naturally, we've observed — as the highlights also point to — mounting pressure in the marketplace when it comes to competition. And on top of that, the upgrade of the product has resulted in — the upgrade of the UnoMeter 500 has resulted in, let's say, near-term consequences for our — for the headway we've managed to make. All of this is — just to pull back for a moment, the UnoMeter 500 was from the start intended to serve as the platform for launching the UnoMeter Safeti Plus product, as we've said on a number of occasions. So at this point, we believe we hold the tools required, since we have the 500 in the more price-aggressive segment and we can also now place the UnoMeter Safeti Plus as the differentiated, unique product that will carry us onward on the revenue journey and on profitability, clearly, as well.

Jorgen Mann

executive
#12

So with that said, let's begin on deliveries. When we discuss what we need to deliver in the second half, the first item is also the most significant one. I've brought it up several times already: UnoMeter Safeti Plus. Getting that product shipping will be a crucial factor for how our revenue and profits develop. And as I've also said, the launch remains on track. In fact, the launch will take place right on schedule. That's been September. Our distributors are keenly anticipating the chance to position this product. They've already gotten what they require to begin market work. This product will additionally open doors for us in a number of geographies that until now have been out of reach, since UnoMeter 500 wasn't a strong product in those geographies. With Safeti Plus, we'll gain access. We will reestablish and build competitiveness in certain markets where we haven't yet been present with UnoMeter 500. And we do expect we can even reach a point where we come close to covering 90% of the prior Convatec geography that they covered with their -- back when they were at the top of their game.

Jorgen Mann

executive
#13

As we've been saying since early in the year, we're now on the journey to establish growth and to broaden our portfolio with additional distributor products. There are a number of specific projects we're working on with partners that should begin contributing to our results in 2025, as expected. Those will bring us both revenue and profit, and beyond that they'll give us greater strength in the markets with our distributors, which is what we need to keep the journey going. Another project that's extremely important to us is getting the due diligence process on the Biim project completed. Both we and the U.S. partner we work with are very focused and determined to get this business done and to move it from a due diligence process into a genuinely real business perspective. We have also already started, before the summer holiday, the ramp-up toward the launch of the UnoMeter Safeti Max — the product with enhanced safety features that focuses heavily on infection risk within the ICU and on the use of urine measurement devices. And we still aim for a Q1 launch of that product.

Jorgen Mann

executive
#14

Another key item involves finishing the repair work, which kicks off late in September and continues into—sorry, into October. There's also a private placement coming from our manufacturer in China. They're keen to participate in the business. They view the opportunity the same way we do and want to be nearer to us along that path. The final point I'd like to raise is something most of you likely already know: given the logistical situation that, shall we say, the world is currently examining, we must also handle it with incoming supplies and with a requirement for expedited deliveries to back our revenue and profit. We have to deal with the logistical complexity now facing us, with very high prices as well as longer delivery times. Our approach here is an active one, but managing this across the second half of the year without costs blowing up or delivery times stretching past what's expected is certainly going to be a challenge. Turning to—providing an outlook on—the financial side. We now foresee, moving ahead, a revenue stream that is diversified.

Jorgen Mann

executive
#15

As we move toward a wider portfolio, revenue will be coming in not just from the 500, not just from the UnoMeter Safeti Plus and the Abdo-Pressure, but also from new products, the UnoMeter Safeti Max, and notably in the second half of next year, the UnoMeter Sippi — all of which are important stepping stones for further expanding our market share. In our market — on gross margin right now, we do see some challenges there with the 500, as mentioned. We also see that Safeti Plus and the Max and the Sippi are exactly what we need to fight this situation, because they are more differentiated, they will offer the uniqueness that we need to be able to boost our profits and thereby support the ambitions we have going forward. We are looking into a Q4 where we will be looking into how do we make sure that we, as an organization, are prepared for the quite strong growth we are expecting in 2025, and therefore, also looking into what kind of competencies do we need within our organization to drive that. We cannot drive that with 5 employees, but we are very conscious that we do this very selectively so that we build the competencies that are needed from a strategic perspective, and we'll continue to have that focus to manage our cost in an effective way.

Jorgen Mann

executive
#16

On the number side, what you're seeing there is expectations of revenue between NOK 100 million and NOK 135 million for next year. And as you'll notice, it's spread across the UnoMeter Safeti Plus and the 500 portfolio, but the distribution business is also beginning to make a difference now. And the Sippi launch in the second half of the year is now included in our forecast going forward as well. In the right-hand corner, you'll see estimated gross margins for the three segments, and that's exactly what I was pointing to earlier. We do forecast profits for the manual UnoMeters — meaning the UnoMeter 500 and Safeti — at around 40%, while the more differentiated portfolio, particularly Sippi, will give us margins that are significantly more interesting from that perspective. And that will have an effect next year, but even more of an effect in the years to come, because Sippi will then expand further. For the distribution business, we've put that in with a margin of around 25%. That's a different situation. We share profits with both the distributors and the original manufacturer. But we're looking to launch innovative products under that umbrella. So we do feel confident that this is the level we'll be able to realize.

Jorgen Mann

executive
#17

Okay, that brings the presentation to a close. So now we’ll move on to some Q&A, if anyone has any.

Analyst

analyst
#18

<<inaudible>>

Jorgen Mann

executive
#19

Several points to address. Sales for the UnoMeter 500 were already announced as beginning in October 2024—'23, apologies. So that's right, though it isn't really something new or unexpected. Regarding how revenue has developed in the UnoMeter segment, we're in fact seeing an increase from H2 of last year through H1 of this year—not a particularly large increase. This ties closely to what you could call a very strong start, when a number of distributors purchased stock sufficient to cover a stretch into 2024. And we also observe, as I said earlier, that market conditions have somewhat held back the momentum of the UnoMeter 500. That's largely the situation we're examining—what we're looking at. So growth is there, just not at the level we require. But we—I believe we—it's reasonable to say that from the outset we indicated Safeti Plus would be the product carrying most of the growth moving forward.

Analyst

analyst
#20

<<foreign_lang>>

Johan Fagerli

executive
#21

<<foreign_lang>>

Jorgen Mann

executive
#22

Thanks for being here for this presentation. Should anything else come up, feel free to reach out using Johan's contact information or mine, and we'll get back to you on any questions that arrive. Many thanks, and enjoy the remainder of your day.

Johan Fagerli

executive
#23

Thanks.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Observe Medical ASA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Observe Medical ASA earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Observe Medical ASA or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.